AMENDMENT NO. 2 TO CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • July 28th, 2022 • ThermoGenesis Holdings, Inc. • Laboratory apparatus & furniture
This Amendment No. 2 to Convertible Promissory Note (this “Amendment No. 2”) by and between ThermoGenesis Holdings, Inc., a Delaware corporation formerly known as Cesca Therapeutics Inc. (the “Company”), and Orbrex (USA) Co. Limited (“Orbrex”), is entered into effective as of July 25, 2022. Capitalized terms not otherwise defined herein shall have the meanings assigned to such terms in the Convertible Promissory Note (as defined below).
